HONG KONG, CHINA - Media OutReach - 27 August 2020 - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, today announced the signing of a letter of intent ("Letter of Intent") with Fosun Industrial Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma Group"; Stock Code: 600196.SH, 02196.HK) to market and supply potentially 10 million doses of BioNTech SE's BNT162 mRNA-based vaccine candidate (the "COVID-19 Vaccine") against SARS-CoV-2 in Hong Kong Special Administrative Region(SAR) and Macau SAR (the "Region").

 

In the collaboration, Jacobson Pharma will provide all relevant support services to Fosun Pharma Group for the marketing, sales and distribution of the COVID-19 Vaccine in Hong Kong and Macau SAR regions through its extensive sales and distribution network amongst the hospital and medical clinic sectors in the region.

 

Mr Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "We much look forward to joining forces with Fosun Pharma Group to market and supply a potentially safe and effective COVID-19 vaccine product to effectively turn the tide of this pandemic in Hong Kong and Macau SAR regions. We will leverage our distribution network and technical resources to ensure swift accessibility of this novel mRNA-based vaccine product to answer the needs of healthcare professionals and the general public. Jacobson is particularly gratified with the opportunity to contribute and play a part in the fight against this COVID-19 pandemic."

 

BioNtech SE is one of the leading mRNA-based biopharmaceutical companies in the world and is currently listed in US Nasdaq (NASDAQ: BNTX). BioNTech SE will supply the vaccines from its GMP-certified mRNA manufacturing facilities in Europe. BioNTech SE and Fosun Pharma Group announced their strategic collaboration on March 13, 2020. Based on the agreement, the two companies are working jointly on the development and commercialization of potential COVID-19 vaccine products based on BioNTech SE's mRNA technology platform in Greater China i.e. Mainland China, Hong Kong and Macau Special Administration Regions as well as Taiwan. The vaccine candidate is a prophylactic biological product, aiming to prevent COVID-19 in adults. A phase 1 trial has already been initiated in China and the treatment of the first participants with one of the vaccine candidates from the BNT162 program, BNT162b1, was announced on August 5, 2020. All 144 participants have already been enrolled in the Phase 1 study.


Talk to Media OutReach today

Let Media OutReach help you achieve your communication goals. Send an email to info@media-outreach.com or click below. You will receive a response within 24 hours.

Contact us now